Cannabinoides

Applications It is a drug which acts as a potent but unselective agonist for the cannabinoid receptor CB1 or CB2.Synthetic Cannabinoids Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package References Yamada., et al.: J. Med. Chem., 39, 1967 (1996),

WIN 55,212-2 Mesylate ((R)-(+)-WIN 55212) is a potent aminoalkylindole cannabinoid (CB) receptor agonist with Kis of 62.3 and 3.3 nM for human recombinant CB1 and CB2 receptors, respectively. Cannabinoid analogue WIN 55,212-2 Mesylate exhibited a novel anticancer effect against human tumors.

RTICBM-189 is a potent, brain-penetrant allosteric modulator of the cannabinoid type-1 (CB1) receptor with a pIC50 of 7.54 in Ca2+ mobilization assay.

Bay 59-3074 is a CB1/CB2 receptor partial agonist (Ki: 48.3/45.5 nM).

CB2R PAM, an oral drug, boosts CB2 receptor response to specific agonists, showing potential in neuropathic pain relief.

Applications 1-(5-Fluoropentyl)-N-tricyclo[3.3.1.13,7]dec-1-yl-1H-indazole-3-carboxamide is a derivative made in the synthesis of fluorescent heterocyclic aminoadamantanes as multifunctional neuroprotective agents. Synthetic cannabinoids References Jacques, J., et al.: Bioorg. Med. Chem., 19, 3935 (2011);

Applications AB-CHMINACA Metabolite M4 is a synthetic cannabinoid. AB-CHMINACA Metabolite M4 is structurally related to AB-FUBINACA, a high affinity ligand of the central CB1 receptor.Synthetic Cannabinoids References Banister, Samuel D., et al.: ACS Chem. Neurosci., 7, 1241 (2016),

Cannabichromevarin is a phytocannabinoid naturally found in very low levels compared to other cannabinoids from which it differs in having a propyl chain in place of a pentyl chain1. Based on its structure, it is believed to act as a potent anandamine inhibitor similarly to cannabichromene, however, the majority of its pharmacological and toxicological properties are currently unknown. In vitro assays have shown cannabichromevarin protect against oxidative stress in vitro in macrophages2. It was recently shown to be effective for treatment-resistant epilepsy in a patented combination with cannabidiol in a recent open-ended clinical trial3.